Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05680558 · ClinicalTrials.gov registry record · Phase 2
Photopheresis in Early-stage Mycosis Fungoides
A Phase 2 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT05680558 is a Phase 2 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides that is actively recruiting participants, run by Columbia University. The registered enrollment target is 74 participants, above the 64-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (16% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05680558, a Phase 2 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performed as a palliative treatment for late stage CTCL. However, recent studies have demonstrated that patients with early stage CTCL may have markers in their blood which were previously observed primarily in late stage disease, such as clonal T cell populations. Considering these findings, the study aims to investigate whether photopheresis therapy may be used earlier in the disease course to produce a clinical response.
Conditions Studied
Interventions
- DRUG UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis
- DEVICE THERAKOS® CELLEX photopheresis system
Study Locations (1)
New York
- Herbert Irving Pavilion - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2021-05-08 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05680558
The ClinicalTrials.gov registry entry for NCT05680558 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 64-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (16% higher). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis is the first listed.
NCT05680558 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05680558 about?
NCT05680558 is a clinical study titled "Photopheresis in Early-stage Mycosis Fungoides". The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performed as a palliative treatment for late stage CTCL. However, recent studies have demonstrated that pati...
What is the current status of trial NCT05680558?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2021-05-08. Estimated completion is 2027-07.
What conditions does trial NCT05680558 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides.
What interventions are being tested in trial NCT05680558?
The interventions under investigation include: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis (DRUG), THERAKOS® CELLEX photopheresis system (DEVICE).
Who is sponsoring clinical trial NCT05680558?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05680558 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
RECRUITING · Phase 2
-
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
RECRUITING · Phase 2
-
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
COMPLETED · Phase 2
-
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
COMPLETED · Phase 2
-
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.